BCR/ABL directly inhibits expression of SHIP, an SH2-containing polyinositol-5-phosphatase involved in the regulation of hematopoiesis

Molecular and Cellular Biology

Volumn 19, Issue 11, 1999, Pages 7473-7480

  Sattler, Martin ^a   Verma, Shalini ^a   Byrne, Christopher H ^a   Shrikhande, Gautam ^a   Winkler, Thomas ^a   Algate, Paul A ^b   Rohrschneider, Larry R ^b   Griffin, James D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; HEMOPOIETIC GROWTH FACTOR; INOSITOL DERIVATIVE; PHOSPHATASE; PROTEIN TYROSINE KINASE INHIBITOR; TETRACYCLINE; THIOL DERIVATIVE;

ANIMAL CELL; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; GENE DISRUPTION; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE LOSS; GENE TARGETING; GRANULOCYTE PRECURSOR; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM;

ANIMALIA; MURINAE;

EID: 0032745240     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.19.11.7473     Document Type: Article

References (66)

1. Afar, D. E., A. Goga, J. McLaughlin, O. N. Witte, and C. L. Sawyers. 1994. Differential complementation of BCR-ABL point mutants with c-Myc. Science 264:424-426.
2. Aman, M. J., T. D. Lamkin, H. Okada, T. Kurosaki, and K. S. Ravichandran. 1998. The inositol phosphatase SHIP inhibits Akt/PKB activation in B cells. J. Biol. Chem. 273:33922-33928.
3. Andoniou, C. E., C. Thien, and W. Y. Langdon. 1994. Tumour induction by activated Abl involves tyrosine phosphorylation of the product of the Cb1 oncogene. EMBO J. 13:4515-4523.
4. Bedi, A., B. A. Zehnbauer, J. P. Barber, S. J. Sharkis, and R. J. Jones. 1994. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 83:2038-2044.
5. Ben-Neriah, V., G. Q. Daley, A. M. Mes-Masson, O. N. Witte, and D. Baltimore. 1986. The chronic myelogenous leukemia-specific p210 protein is the product of the BCR/ABL hybrid gene. Science 233:212-214.
6. Burgess, G. S., E. A. Williamson, L. D. Cripe, S. Litz-Jackson, J. A. Bhatt, K. Stanley, M, J. Stewart, A. S. Kraft, H. Nakshatri, and H. S. Boswell. 1998. Regulation of the c-jun gene in p210 BCR-ABL transformed cells corresponds with activity of JNK, the c-jun N-terminal kinase. Blood 92:2450-2460.
7. Canellos, G. 1991. Diagnosis and treatment of chronic granulocytic leukemia, p. 61-76. In P. H. Wiernik, G. P. Canellos, R. A. Kyle, et al. (ed.). Neoplastic disease of the blood. Churchill Livingstone, New York, N.Y.
8. Carlesso, N., D. A. Frank, and J. D. Griffin. 1996. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by BCR/ ABL J. Exp. Med. 183:811-820.
9. Chacko, G. W., S. Tridandapani, J. E. Damen, L. Liu, G. Krystal, and K. M. Coggeshall. 1996. Negative signaling in B lymphocytes induces tyrosine phosphorylation of the 145-kDa inositol polyphosphate 5-phosphatase. SHIP. J. Immunol. 157:2234-2238.
10. Daheron, L., S. Salmeron, S. Patri, A. Brizard, F. Guilhot, J. C. Chomel, and A. Kitzis. 1998. Identification of several genes differentially expressed during progression of chronic myelogenous leukemia. Leukemia 12:326-332.
11. Dai, Z. H., and A. M. Pendergast. 1995. Abi-2, a novel SH3-containing protein interacts with the c-Abl tyrosine kinase and modulates c-Abl transforming activity. Genes Dev. 9:2569-2582.
12. Dai, Z. H., R. C. Quackenbush, K. D. Courtney, M. Grove, D. Cortez, G. W. Reuther, and A. M. Pendergast. 1998. Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway. Genes Dev. 12:1415-1424.
13. Daley, G. Q., R. A. Van Etten, and D. Baltimore. 1990. Induction of chronic myelogenous leukemia in mice by the p210BCR/ABL gene of the Philadelphia chromosome. Science 247:824-830.
14. Damen, J. E., L. Liu, P. Rosten, R. K. Humphries, A. B. Jefferson, P. W. Majerus, and G. Krystal. 1996. The 145-kDa protein induced to associate with Shc by multiple cylokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase. Proc. Natl. Acad. Sci. USA 93:1689-1693.
15. Damen, J. E., L. Liu, M. D. Ware, M. Ermolaeva, P. W. Majerus, and G. Krystal. 1998. Multiple forms of the SH2-containing inositol phosphatase, SHIP, are generated by C-terminal truncation. Blood 92:1199-1205.
16. Dick, L. R., A. A. Cruikshank, A. T. Destree, L. Grenier, T. A. McCormack, F. D. Melandri, S. L. Nunes, V. J. Palombella, L. A. Parent, L. Plamondon, and R. L. Stein. 1997. Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells. J. Biol. Chem. 272:182-188.
17. Druker, B. J., S. Tamura, E. Buchdunger, S. Ohno, G. M. Segal, S. Fanning, J. Zimmermann, and N. B. Lydon. 1996. Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells. Nat. Med. 2:561-566.
18. Elefanty, A. G., I. K. Hariharan, and S. Cory. 1990. BCR-ABL, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J. 9:1069-1078.
19. Fruman, D. A., S. B. Snapper, C. M. Yballe, L. Davidson, J. Y. Yu, F. W. Alt, and L. C. Cantley. 1999. Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85 alpha. Science 283:393-397.
20. Gharehbaghi, K., G. S. Burgess, F. R. Collart, S. Litz-Jackson, E. Huberman, H. N. Jayaram, and H. S. Boswell. 1994. p210 BCR-ABL confers overexpression of inosine monophosphate dehydrogenase: an intrinsic pathway to drug resistance mediated by oncogene. Leukemia 8:1257-1263.
21. Golub, T. R., A. Goga, G. F. Barker, D. Afar, J. McLaughlin, S. K. Bohlander, J. D. Rowley, O. N. Witte, and D. G. Gilliland. 1996. Oligomerization of the Abl tyrosine kinase by the Ets protein Tel in human leukemia. Mol. Cell. Biol. 16:4107-4116.
22. Gordon, M. Y., C. R. Dowding, G. P. Riley, J. M. Goldman, and M. F. Greaves. 1987. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature 328:342-344.
23. Grignani, F., T. Kinsella, A. Mencarelli, M. Valtieri, D. Riganelli, F. Grignani, L Lanfrancone, C. Peschle, G. P. Nolan, and P. G. Pelicci. 1998. High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid ebv/retroviral vector expressing the green fluorescence protein. Cancer Res. 58:14-19.
24. Habib, T., J. A. Hejna, R. E. Moses, and S. J. Decker. 1998. Growth factors and insulin stimulate tyrosine phosphorylation of the 51C/SHIP2 protein. J. Biol. Chem. 273:18605-18609.
25. Heisterkamp, N., G. Jenster, J. ten Hoeve, D. Zovich, P. K. Pattengale, and J. Groffen. 1990. Acute leukaemia in BCR/ABL transgenic mice. Nature 344:251-253.
26. Heisterkamp, N., J. R. Stephenson, J. Groffen, P. F. Hansen, A. de Klein, C. R. Bartram, and G. Grosveld. 1983. Localization of the c-Abl oncogene adjacent to a translocation breakpoint in chronic myelocytic leukaemia. Nature 306:239-242.
27. Hejna, J. A., H. Saito, L. S. Merkens, T. V. Tittle, P. M. Jakobs, M. A. Whitney, M. Grompe, A. S. Friedberg, and R. E. Moses. 1995. Cloning and characterization of a human cDNA (INNPL1) sharing homology with inositol polyphosphate phosphatases. Genomics 29:285-287.
28. Helgason, C. D., J. E. Damen, P. Rosten, R. Grewal, P. Sorensen, S. M. Chappel, A. Borowski, F. Jirik, G. Krystal, and R. K. Humphries. 1998. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev. 12:1610-1620.
29. Hunter, M. G., and B. R. Avalos. 1998. Phosphatidylinositol 3′-kinase and SH2-containing inositol phosphatase (SHIP) are recruited by distinct positive and negative growth-regulatory domains in the granulocyte colony-stimulating factor receptor. J. Immunol. 160:4979-4987.
30. BCR/ABL induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J. Biol. Chem. 271:31704-31710.
31. + cells from patients with chronic myelogenous leukemia (CML). Blood Suppl. 90:254a.
32. Kelliher, M. A., J. McLaughlin, O. N. Witte, and N. Rosenberg. 1990 Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc. Natl. Acad. Sci. USA 87:6649-6653.
33. Klucher, K. M., D. V. Lopez, and G. Q. Daley. 1998. Secondary mutation maintains the transformed state in BaF3 cells with inducible Bcr/Abl expression. Blood 91:3927-3934.
34. Lamontagne, K. R., A. J. Flint, B. R. Franza, A. M. Pendergast, and N. K. Tonks. 1998. Protein tyrosine phosphatase 1B antagonizes signalling by oncoprotein tyrosine kinase p210 bcr-abl in vivo. Mol. Cell. Biol. 18:2965-2975.
35. Lioubin, M. N., P. A. Algate, S. Tsai, K. Carlberg, R. Aebersold, and L. R. Rohrschneider. 1996. p150-SHIP, a signal transduction molecule with inositol polyphosphate-5-phosphatase activity. Genes Dev. 10:1084-1095.
36. Lucas, D. M., and L. R. Rohrschneider. 1999. A novel spliced form of SH2-containing inositol phosphatase is expressed during myeloid development. Blood 93:1922-1933.
37. BCR/ABL. J. Biol. Chem. 269:5016-5021.
38. McWhirter, J. R., D. L. Galasso, and J. Y. Wang. 1993. A coiled-coil oligomerization domain of BCR is essential for the transforming function of BCR-ABL oncoproteins. Mol. Cell. Biol. 13:7587-7595.
39. Odai, H., K, Sasaki, A. Iwamatsu, Y. Hanazono, T. Tanaka, K. Mitani, Y. Yazaki, and H. Hirai. 1995. The proto-oncogene product c-Cbl becomes tyrosine phosphorylated by stimulation with GM-CSF or EPO and constitutively binds to the SH3 domain of GRB2/ASH in human hematopoietic cells. J. Biol. Chem. 270:10800-10805.
40. Osborne, M. A., G. Zenner, M. Lubinus, X. L. Zhang, Z. Songyang, L. C. Cantley, P. Majerus, P. Burn, and J. P. Kochan. 1996. The inositol 5′-phosphatase SHIP binds to immunoreceptor signaling motifs and responds to high affinity IgE receptor aggregation. J. Biol. Chem. 271:29271-29278.
41. Pear, W. S., G. P. Nolan, M. L. Scott, and D. Baltimore. 1993. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA 90:8392-8396.
42. Pendergast, A. M., L. A. Quilliam, L. D. Cripe, C. H. Bassing, Z. Dai, N. Li, A. Batzer, K. M. Rabun, C. J. Der, J. Schlessinger, and M. L. Gishizkv. 1993. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75:175-185.
43. Pesesse, X., S. Deleu, F. Desmedt, L. Drayer, and C. Erneux. 1997. Identification of SL second SH2-domain-containing protein closely related to the phosphatidylinositol polyphosphate 5-phosphatase SHIP. Biochem. Biophys. Res. Commun. 239:697-700.
44. Puil, L., J. Liu, G. Gish, G. Mbamalu, D. Bowtell, P. G. Pelicci, R. Arlinghaus, and T. Pawson. 1994. BCR-ABL oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J. 13:764-773.
45. Renshaw, M. W., J. R. McWhirter, and J. Y. Wang. 1995. The human leukemia oncogene BCR-ABL abrogates the anchorage requirement but not the growth factor requirement for proliferation. Mol. Cell. Biol. 15:1286-1293.
46. Rock, K. L., C. Gramm, L. Rothstein, K. Clark, R. Stein, L. Dick, D. Hwang, and A. L. Goldberg. 1994. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78:761-771.
47. Rowley, J. D. 1973. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290-293.
48. Salgia, R., J. L. Li, D. S. Ewaniuk, W. Pear, E. Pisick, S. A. Burky, T. Ernst, M. Sattler, L. B. Chen, and J. D. Griffin. 1997. BCR/ABL induces multiple abnormalities of cytoskeletal function. J. Clin. Investig. 100:46-57.
49. BCR/ABL. J. Biol. Chem. 270:5039-5047.
50. Sattler, M., M. A. Durstin, D. A. Frank, K. Okuda, K. Kaushansky, R. Salgia, and J. D. Griffin. 1995. The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases. Exp. Hematol. 23:1040-1048.
51. CBL. J. Cell. Physiol. 171:28-33.
52. Sattler, M., R. Salgia, G. Shrikhande, S. Verma, J. L. Choi, L. R. Rohrschneider, and J. D. Griffin. 1997. The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors. Oncogene 15:2379-2384.
53. Sattler, M., T. Winkler, S. Verma, C. H. Byrne, G. Shrikhande, R. Salgia, and J. D. Griffin. 1999. Hematopoietic growth factors signal through the formation of reactive oxygen species. Blood 93:2928-2935.
54. Serve, H., N. S. Yee, G. Stella, L. Sepp-Lorenzino, J. C. Tan, and P. Besmer. 1995. Differential roles of PI3-kinase and Kit tyrosine 821 in Kit receptor-mediated proliferation, survival and cell adhesion in mast cells. EMBO J. 14:473-483.
55. Shi, Y. G., K. Alin, and S. P. Goff. 1995. Abl-interactor-1, a novel SH3 protein binding to the carboxy-terminal portion of the Abl protein, suppresses v-Abl transforming activity. Genes Dev. 9:2583-2597.
56. Shtivelman, E., B. Lifshitz, R. P. Gale, and E. Canaani. 1985. Fused transcript of Abl and Bcr genes in chronic myelogenous leukaemia. Nature 315:550-554.
57. Shuai, K., J. Halpern, J. ten Hoeve, X. P. Rao, and C. L. Sawyers. 1996. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 13:247-254.
58. Skorski, T., P. Kanakaraj, M. Nieborowska-Skorska, M. Z. Ratajczak, S. C. Wen, G. Zon, A. M. Gewirtz, B. Perussia, and B. Calabretta. 1995. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 86:726-736.
59. Srinivasan, S., M. Seaman, Y. Nemoto, L. Daniell, S. F. Suchy, S. Emr, P. Decamilli, and R. Nussbaum. 1997. Disruption of three phosphatidylinositol-polyphosphate 5-phosphatase genes from Saccharomyces cerevisiae results in pleiotropic abnormalities of vacuole morphology, cell shape, and osmohomeostasis. Eur. J. Cell Biol. 74:350-360.
60. Stewart, M. J., S. Litz-Jackson, G. S. Burgess, E. A. Williamson, D. S. Leibowitz, and H. S. Boswell. 1995. Role for E2F1 in p210 BCR-ABL downstream regulation of c-myc transcription initiation. Studies in murine myeloid cells. Leukemia 9:1499-1507.
61. Suzuki, H., Y. Terauchi, M. Fujiwara, S. Aizawa, Y. Yazaki, T. Kadowaki, and S. Koyasu, 1999. Xid-like immunodeficiency in mice with disruption of the p85 alpha subunit of phosphoinositide 3-kinase. Science 283:390-392.
62. Traenckner, E. B., S. Wilk, and P. A. Baeuerle. 1994. A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B. EMBO J. 13:5433-5441.
63. Verfaillie, C. M., R. Hurley, B. I. Lundell, C. H. Zhao, and R. Bhatia. 1997. Integrin-mediated regulation of hematopoiesis - do BCR/ABL-induced defects in integrin function underlie the abnormal circulation and proliferation of CML progenitors. Acta Haematol. 97:40-52.
64. Verfaillie, C. M., J. B. McCarthy, and P. B. McGlave. 1992. Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. J. Clin. Investig. 90:1232-1241.
65. Vollenweider, P., M. Clodi, S. S. Martin, T. Imamura, W. M. Kavanaugh, and J. M. Olefsky. 1999. An SH2 domain-containing 5 ′ inositolphosphatase inhibits insulin-induced GLUT4 translocation and growth factor-induced actin filament rearrangement. Mol. Cell. Biol. 19:1081-1091.
66. Wisniewski, D., A. Strife, S. Swendeman, H. Erdjument-Bromage, S. Geromanos, W. M. Kavanaugh, P. Tempst, and B. Clarkson. 1999. A novel SH2-containing phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase (SHIP2) is constitutively tyrosine phosphorylated and associated with src homologous and collagen gene (SHC) in chronic myelogenous leukemia progenitor cells. Blood 93:2707-2720.